"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.
https://bit.ly/4t4hyN6
#ASH25
https://bit.ly/4t4hyN6
#ASH25
Significant Barriers to Health Literacy Exist for Patients With Thalassemia
Researchers determined there may be overestimation of disease understanding and barriers to health literacy among patients with thalassemia.
bit.ly
January 27, 2026 at 8:35 PM
"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.
https://bit.ly/4t4hyN6
#ASH25
https://bit.ly/4t4hyN6
#ASH25
From #ASH25: We break down the 10 most impactful myeloma breakthroughs, including advances in CAR T-cell therapy and bispecific antibodies and what this latest research means for people living with myeloma. Watch now: mmsm.link/4qeZrlU
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
January 8, 2026 at 11:28 PM
From #ASH25: We break down the 10 most impactful myeloma breakthroughs, including advances in CAR T-cell therapy and bispecific antibodies and what this latest research means for people living with myeloma. Watch now: mmsm.link/4qeZrlU
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
What stood out in leukemias at #ASH25?
In this PulseCast episode, Amir T. Fathi, MD, reviews key studies and discusses how emerging data may inform care for patients with AML and CML.
Listen to the full episode here: https://bit.ly/4p4m9vM
In this PulseCast episode, Amir T. Fathi, MD, reviews key studies and discusses how emerging data may inform care for patients with AML and CML.
Listen to the full episode here: https://bit.ly/4p4m9vM
December 28, 2025 at 6:18 PM
What stood out in leukemias at #ASH25?
In this PulseCast episode, Amir T. Fathi, MD, reviews key studies and discusses how emerging data may inform care for patients with AML and CML.
Listen to the full episode here: https://bit.ly/4p4m9vM
In this PulseCast episode, Amir T. Fathi, MD, reviews key studies and discusses how emerging data may inform care for patients with AML and CML.
Listen to the full episode here: https://bit.ly/4p4m9vM
Looking forward to participating in this forum about the great #myeloma studies coming out of ASH this month! So many reasons to be hopeful! #mmsm #IMFASH25 #ASH25
What’s New in #Myeloma Research?
Join our speakers online on Wednesday, January 7, 2026, to hear about the top myeloma research presented at ASH— all from a patient perspective. Register before spots are gone: https://mmsm.link/4pOxSz1
#IMFASH25 #ASH25 #mmsm
Join our speakers online on Wednesday, January 7, 2026, to hear about the top myeloma research presented at ASH— all from a patient perspective. Register before spots are gone: https://mmsm.link/4pOxSz1
#IMFASH25 #ASH25 #mmsm
December 26, 2025 at 10:29 PM
@rahulbanerjeemd.bsky.social of @fredhutch.org discusses major advances in bispecific antibodies presented at #ASH25 for #multipleMyeloma.
Read and watch more here: ➡️ https://bit.ly/3KMNsg0
#myeloma #mmsm
Read and watch more here: ➡️ https://bit.ly/3KMNsg0
#myeloma #mmsm
December 15, 2025 at 8:53 PM
@rahulbanerjeemd.bsky.social of @fredhutch.org discusses major advances in bispecific antibodies presented at #ASH25 for #multipleMyeloma.
Read and watch more here: ➡️ https://bit.ly/3KMNsg0
#myeloma #mmsm
Read and watch more here: ➡️ https://bit.ly/3KMNsg0
#myeloma #mmsm
Can dietary changes delay progression from precursor disorders to a cancer - myeloma? Excited to share our manuscript is published online @aacrjournals.bsky.social
Cancer Discovery @mskcancercenter.bsky.social
#mmsm #ASH25
tinyurl.com/43x8h35p
Cancer Discovery @mskcancercenter.bsky.social
#mmsm #ASH25
tinyurl.com/43x8h35p
December 13, 2025 at 7:09 PM
Can dietary changes delay progression from precursor disorders to a cancer - myeloma? Excited to share our manuscript is published online @aacrjournals.bsky.social
Cancer Discovery @mskcancercenter.bsky.social
#mmsm #ASH25
tinyurl.com/43x8h35p
Cancer Discovery @mskcancercenter.bsky.social
#mmsm #ASH25
tinyurl.com/43x8h35p
Epcoritamab reduced the risk for death by 79%. Presented at #ASH25, by Dr Falchi of @mskcancercenter.bsky.social covered by @cancertherapyadv.bsky.social.
https://bit.ly/4q4fQcb
#lymsm #follicularLymphoma
https://bit.ly/4q4fQcb
#lymsm #follicularLymphoma
December 13, 2025 at 9:11 PM
Epcoritamab reduced the risk for death by 79%. Presented at #ASH25, by Dr Falchi of @mskcancercenter.bsky.social covered by @cancertherapyadv.bsky.social.
https://bit.ly/4q4fQcb
#lymsm #follicularLymphoma
https://bit.ly/4q4fQcb
#lymsm #follicularLymphoma
Delayed side effects after CAR T therapy for multiple myeloma—including neurotoxicity and intestinal inflammation—may share a common immune root cause. New Penn Medicine research presented at #ASH25 links them to higher non-relapse mortality. https://bit.ly/4a5QJ4c
December 12, 2025 at 7:47 PM
Delayed side effects after CAR T therapy for multiple myeloma—including neurotoxicity and intestinal inflammation—may share a common immune root cause. New Penn Medicine research presented at #ASH25 links them to higher non-relapse mortality. https://bit.ly/4a5QJ4c
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML | OncLive
TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.
www.onclive.com
December 12, 2025 at 5:19 PM
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...
Still exploring #ASH25? The virtual meeting platform is open through the end of your registration period. Rewatch sessions and discover anything you missed. Watch now: https://ow.ly/oxUB50XHCKM
December 11, 2025 at 9:20 PM
Still exploring #ASH25? The virtual meeting platform is open through the end of your registration period. Rewatch sessions and discover anything you missed. Watch now: https://ow.ly/oxUB50XHCKM
Combining asciminib, a first-in-class BCL::ABL1 inhibitor, with a TKI shows increasing efficacy and tolerability over 3 years in #CML, with some patients able to enter treatment-free remission. Presented at #ASH25.
https://bit.ly/4pV8Le2
#leusm
https://bit.ly/4pV8Le2
#leusm
December 11, 2025 at 3:55 PM
Combining asciminib, a first-in-class BCL::ABL1 inhibitor, with a TKI shows increasing efficacy and tolerability over 3 years in #CML, with some patients able to enter treatment-free remission. Presented at #ASH25.
https://bit.ly/4pV8Le2
#leusm
https://bit.ly/4pV8Le2
#leusm
Congratulations to @mafdawson.bsky.social for being awarded the Dameshek Prize by @ash.hematology.org at #ASH25!
December 10, 2025 at 2:13 AM
Congratulations to @mafdawson.bsky.social for being awarded the Dameshek Prize by @ash.hematology.org at #ASH25!
Great to meet Leena Babiker at @astct.bsky.social booth. She gave great talk at Winter Workshop and will defending her PhD next spring. #ash25
December 10, 2025 at 1:57 AM
Great to meet Leena Babiker at @astct.bsky.social booth. She gave great talk at Winter Workshop and will defending her PhD next spring. #ash25
The Lymphoma Hub was pleased to speak with Adelba Torres at #ASH25. We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the use of bispecific antibodies in an ethnically/racially diverse group of patients?
Watch here: https://loom.ly/fmtCMPg
#lymsm #lymphoma #MedEd
Watch here: https://loom.ly/fmtCMPg
#lymsm #lymphoma #MedEd
December 10, 2025 at 10:30 AM
The Lymphoma Hub was pleased to speak with Adelba Torres at #ASH25. We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the use of bispecific antibodies in an ethnically/racially diverse group of patients?
Watch here: https://loom.ly/fmtCMPg
#lymsm #lymphoma #MedEd
Watch here: https://loom.ly/fmtCMPg
#lymsm #lymphoma #MedEd
Inside ASH25 with Talha Badar
@ash.hematology.org
@talhabadarmd.bsky.social
oncodaily.com/voices/ash25...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASH #ASH25 #ASH2025
@ash.hematology.org
@talhabadarmd.bsky.social
oncodaily.com/voices/ash25...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASH #ASH25 #ASH2025
Inside ASH25 with Talha Badar - OncoDaily
Inside ASH25 with Talha Badar / ASH, ASH 2025, ASH25, cancer, Headlines, OncoDaily, Oncology, Talha Badar
oncodaily.com
December 9, 2025 at 8:54 PM
Inside ASH25 with Talha Badar
@ash.hematology.org
@talhabadarmd.bsky.social
oncodaily.com/voices/ash25...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASH #ASH25 #ASH2025
@ash.hematology.org
@talhabadarmd.bsky.social
oncodaily.com/voices/ash25...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASH #ASH25 #ASH2025
Great to reconnect with the AAMDS Foundation at #ASH25 as we continue to share a commitment to advancing education and support for patients with bone marrow failure disorders.
#AAMDS #Hematology #ASH2025 #HemeHub #BoneMarrowFailure
#AAMDS #Hematology #ASH2025 #HemeHub #BoneMarrowFailure
December 10, 2025 at 1:02 AM
Great to reconnect with the AAMDS Foundation at #ASH25 as we continue to share a commitment to advancing education and support for patients with bone marrow failure disorders.
#AAMDS #Hematology #ASH2025 #HemeHub #BoneMarrowFailure
#AAMDS #Hematology #ASH2025 #HemeHub #BoneMarrowFailure
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome - OncoDaily
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome / Agent Orange, American Society of Hematology,
oncodaily.com
December 9, 2025 at 8:58 PM
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
Feeling great to have presented my work at #ASH25. What an amazing conference this has been! Thank you for the wonderful opportunity! Looking forward to the ASH meeting next year and hope to showcase again our work from @danafarber.bsky.social
#Hematology #leusm #lymsm #ashawards #NKCell
#Hematology #leusm #lymsm #ashawards #NKCell
December 9, 2025 at 9:36 PM
Feeling great to have presented my work at #ASH25. What an amazing conference this has been! Thank you for the wonderful opportunity! Looking forward to the ASH meeting next year and hope to showcase again our work from @danafarber.bsky.social
#Hematology #leusm #lymsm #ashawards #NKCell
#Hematology #leusm #lymsm #ashawards #NKCell
✨ #ASH25 : Résultats sans précédent de l'étude #MajesTEC_3 : #Tecvayli associé à #Darzalex Faspro pourrait devenir un nouveau standard dès la deuxième ligne chez les patients atteints de #MyélomeMultiple 🩸 en R/R
www.zonebourse.com/actualite-bo...
www.zonebourse.com/actualite-bo...
December 9, 2025 at 3:42 PM
✨ #ASH25 : Résultats sans précédent de l'étude #MajesTEC_3 : #Tecvayli associé à #Darzalex Faspro pourrait devenir un nouveau standard dès la deuxième ligne chez les patients atteints de #MyélomeMultiple 🩸 en R/R
www.zonebourse.com/actualite-bo...
www.zonebourse.com/actualite-bo...
We were at #ASH25 in Orlando! Yesterday we presented our abstract on MPN Journal, a patient-driven platform for better tracking, communication, and real-world data. Huge thanks to @rubenmesamd.bsky.social, winner of the Ernest Beutler Prize, for supporting our work. #MPNJournal #PatientEmpowerment
December 9, 2025 at 3:10 PM
We were at #ASH25 in Orlando! Yesterday we presented our abstract on MPN Journal, a patient-driven platform for better tracking, communication, and real-world data. Huge thanks to @rubenmesamd.bsky.social, winner of the Ernest Beutler Prize, for supporting our work. #MPNJournal #PatientEmpowerment
Johann-Christoph Jann, MD, presents new research on the activation of endogenous retroviral elements that may drive inflammation and cellular transformation in STAG2-mutant myeloid malignancies. @tothovalab.bsky.social #ASH25
December 8, 2025 at 10:04 PM
Johann-Christoph Jann, MD, presents new research on the activation of endogenous retroviral elements that may drive inflammation and cellular transformation in STAG2-mutant myeloid malignancies. @tothovalab.bsky.social #ASH25